Aqemia

Aqemia is a next-generation pharmatech company founded in 2019 as a deeptech spinoff from École Normale Supérieure that revolutionizes drug discovery by combining quantum-inspired physics algorithms with generative AI, enabling molecule exploration 10,000 times faster than conventional methods without requiring experimental training data. In 2024, Aqemia raised €60 million in Series A funding led by Cathay Innovation, bringing total funding to over €100 million, to prepare for clinical trials and fuel international expansion with a new London office opening in January 2025. The company currently has three cancer-targeting drug candidates undergoing preclinical animal testing, having progressed to this stage in under two years with expectations to move into clinical trials by 2025. Aqemia's quantum-inspired algorithms simulate molecular behavior at unprecedented accuracy and speed, training AI models on physical laws governing molecular structures. Major partnerships include a $140 million collaboration with Sanofi and agreements with Servier and Johnson & Johnson to accelerate oncology drug development through physics-based molecular design.